Imbruvica Market Size, Share | Industry Growth Report, 2019-2025

The Global Imbruvica Market was valued at USD 6.20 billion in 2018. Emergence of novel cancer therapies and targeted therapy for rising number of patients with lymphomas and leukemia are the prime factors for the growth of the global Imbruvica market.

Get more Information about this Report @ https://www.adroitmarketresearch.com/industry-reports/imbruvica-market

Targeted cancer therapies are drugs that restrain the development and spread of cancer by interfering with particularmolecules ("molecular targets") that take part in the growth, progression, and metastasis of cancer. Targeted drugs specifically attack malignant cells or precise targets, unlike traditional chemotherapy drugs, which randomly attack healthy cells as well as cancer cells. These days much attention is being given to anti-cancer targeted drugs, under development. These drugs are often the cornerstone of precision medicine, as they use genetic information to prevent, diagnose and treat diseases. Imbruvica targets Bruton's tyrosine kinase (BTK) by blocking its activity. This inhibits the communication signals within B cells, which in turn transports malignant B cells out of their nourishing environment from the lymph nodes, bone marrow and other organs.

Request Sample Pages for more Insights @ https://www.adroitmarketresearch.com/contacts/request-sample/839

Imbruvica is approved for the treatment of Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Waldenström's Macroglobulinemia (WM), Relapsed/Refractory Marginal Zone Lymphoma (RR MZL) and Chronic Graft-Versus-Host-Disease (cGVHD). CLL accounted for majority market share in 2018 and is expected to retain its position by 2025 with 55.9% market share. CLL is the most common blood cancer in people aged 70 and above. However, the incidence of the disease ranges from 30/100,000 in individuals aged 80 years and older.

U.S. is a major hub for Imbruvica market due to presence of prominent players, large patient pool and supportive government initiatives. It also holds patent exclusivity for Imbruvica. Smoking, exposure to certain chemicals, radiation and obesity are the foremost risk factors associated with blood cancers in the U.S. However, efforts are being undertaken to promote healthy lifestyles which will significantly drop down the incidence rates of blood cancer. Imbruvica players in the United States include Janssen Pharmaceuticals, Inc. and Pharmacyclics LLC (an AbbVie Company).

For Any Query on the Imbruvica market @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/839
Key Segments of the Global Imbruvica Market

Application Overview, 2015-2025 (USD Million)
• Mantle Cell Lymphoma
• Chronic Lymphocytic Leukaemia
• Waldenström's Macroglobulinemia
• Relapsed/Refractory Marginal Zone Lymphoma
• Chronic Graft-Versus-Host-Disease

Regional Overview, 2015-2025 (USD Million)
• U.S
• Europe
• India
• Japan
• China
• Southeast Asia
• Central & South America

Reasons for the study
• With resistant strains of disease, genetic differences in patients and the requirement for more effective yet less damaging treatment options, modern medicine is beginning to change its approach
• The rising practice of combinational therapy
• ANDA approval for Ibrutinib
• Increasing number of targeted therapies in hematological malignancies

About us:
We are here to provide credible market intelligence with actionable insights. We believe that with the fast changing business environment and rapid turns in economic cycles, a lot is overlooked. With the aid of technology, a large amount of data is produced which is waiting to be analyzed and patterned. The insights which can be mined from such a large amount of data can enable businesses to grow at a pace of their choosing, be it long term goals or short-term goals. Being aware of the market movements allows for agility and agility is one of the highest rated characteristics of modern businesses.

Contact us:
Contact Name: Ryan Johnson
Contact Email: sales@adroitmarketresearch.com
Contact Phone: +1 (214) 884-6068

This release was published on openPR.